Royalty Pharma Manager, LLC

The firm acquires royalty interests in pharmaceutical and biotech products, including both approved drugs and those in clinical development. It provides financing to drug developers in exchange for a share of future revenues, typically structured as a percentage of net sales. This strategy generates returns driven by drug lifecycle cash flows rather than equity appreciation.

The firm targets both approved and late-stage clinical assets. Approved drugs provide predictable revenue streams, while milestone-based royalties on development-stage programs offer upside from regulatory and commercial success. This dual approach balances current yield with growth optionality.

Deal flow originates from pharmaceutical companies, academic research institutions, and inventors seeking non-dilutive capital. The firm also purchases existing royalty obligations from original holders. The royalty model allows innovators to monetize future earnings without relinquishing equity or control.

The firm concentrates on the United States and Europe, where strong patent enforcement and regulatory clarity protect royalty streams. These regions also host a high density of pharmaceutical innovators and commercial-stage biotech companies.